文献速递炎症性肠病

将粪便钙卫蛋白纳入中重度溃疡性结肠炎生物制剂或小分子抑制剂治疗的临床实践

Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

该研究采用GRADE框架,基于英夫利西单抗、戈利木单抗、维得利珠单抗和托法替布治疗溃疡性结肠炎(UC)的试验个体参与者数据,结合粪便钙卫蛋白(FC)性能的系统评价,评估FC替代内镜监测中重度UC患者治疗反应的性能。预设假阴性(FN)和假阳性(FP)可接受阈值均为5%。结果显示,在直肠出血评分(RBS)0且排便频率评分(SFS)0/1的患者中,FC≤50 μg/g可避免约50%患者内镜且FN率<5%;在RBS 2/3且SFS 2/3的患者中,FC≥250 μg/g可避免约50%患者内镜且FP率<5%;但RBS 0且SFS 2/3的患者FN和FP率均持续>10%,需内镜评估。

要点

  • RBS 0且SFS 0/1时,FC≤50 μg/g可避免约50%内镜且FN率<5%。
  • RBS 2/3且SFS 2/3时,FC≥250 μg/g可避免约50%内镜且FP率<5%。
  • RBS 0但SFS 2/3时FC诊断不确定性大,FN和FP率均>10%,建议内镜。

核心结论

  • 在中重度UC患者中,FC可在两种临床场景下可靠替代内镜监测生物制剂或托法替布的治疗反应。

研究设计与样本

  • 采用GRADE框架,汇总英夫利西单抗、戈利木单抗、维得利珠单抗和托法替布治疗UC的试验个体参与者数据,结合FC性能的系统评价。

主要发现

  • RBS 0且SFS 0/1时,FC≤50 μg/g可避免约50%患者内镜,FN率<5%。
  • RBS 2/3且SFS 2/3时,FC≥250 μg/g可避免约50%患者内镜,FP率<5%。
  • RBS 0但SFS 2/3时,FC的FN和FP率均持续>10%。

关键数值与推荐

  • 预设FN和FP可接受阈值均为5%。
  • FC≤50 μg/g适用于RBS 0且SFS 0/1的患者。
  • FC≥250 μg/g适用于RBS 2/3且SFS 2/3的患者。
  • RBS 0且SFS 2/3的患者建议内镜评估。

临床怎么用

  • 对RBS 0且SFS 0/1的UC患者,FC≤50 μg/g时可暂免内镜监测治疗反应。
  • 对RBS 2/3且SFS 2/3的UC患者,FC≥250 μg/g时可暂免内镜。
  • 对RBS 0但SFS 2/3的UC患者,应行内镜评估而非仅依赖FC。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We applied the Grading of Recommendations, Assessment, Development, and Evaluation framework to evaluate the performance of fecal calprotectin (FC) as an alternative to endoscopy in patients with moderate-to-severe ulcerative colitis (UC) treated with a biologic agent or tofacitinib. METHODS: Individual participant data from the trials of infliximab, golimumab, vedolizumab, and tofacitinib for UC were pooled to generate prevalence of endoscopic activity (Mayo endoscopy score) across different combinations of the rectal bleeding score (RBS) and stool frequency score (SFS). These estimates were then combined with the data from an updated systematic review of the operating properties of FC to generate clinical scenario-specific assessments of the performance of FC as a predictor of endoscopic disease activity. A prespecified threshold of acceptability for false-negative (FN) and false-positive (FP) test results was set at 5%. RESULTS: For patients with UC achieving RBS 0 + SFS 0/1, FC ≤ 50 μg/g may avoid endoscopy in 50% patients with a FN rate <5%. Similarly, for patients with RBS 2/3 + SFS 2/3, FC ≥ 250 μg/g potentially avoids endoscopy in approximately 50% patients with an FP rate <5%. The greatest uncertainty in the diagnostic performance for FC was observed in patients with UC achieving RBS 0 but having SFS 2/3, where FN and FP rates were consistently >10%, and endoscopic evaluation may be warranted. DISCUSSION: Two clinical scenarios were identified where FC can be used with confidence for monitoring treatment response to biologics or tofacitinib in patients with UC without the requirement for endoscopy.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Dulai PS, Battat R, Barsky M, et al. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. Am J Gastroenterol. 2020. PMID: 32384283. doi:10.14309/ajg.0000000000000596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。